Summary
In 2024, the 7MM reported an estimated 772K new cases of postoperative ileus.
FDA-approved treatment options include metoclopramide (REGLAN), neostigmine (PROSTIGMIN), and alvimopan (ENTEREG), all of which face generic competition, with alvimopan losing market exclusivity in 2024.
The development pipeline for postoperative ileus remains sparse, with only a handful of mid-stage candidates, including ORE-001 (lidocaine) and TU-100 (Daikenchuto/TJ-100) in Phase II trials, highlighting slow therapeutic advancement and limited innovation.
The 7MM market for postoperative ileus was valued at approximately USD 3.7 billion in 2024 and is expected to grow ...
